Rankings
▼
Calendar
NAGE Q3 2024 Earnings — Niagen Bioscience Inc Revenue & Financial Results | Market Cap Arena
NAGE
Niagen Bioscience Inc
$423M
Q3 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$26M
+31.2% YoY
Gross Profit
$16M
63.5% margin
Operating Income
$2M
6.3% margin
Net Income
$2M
7.3% margin
EPS (Diluted)
$0.02
QoQ Revenue Growth
+12.5%
Cash Flow
Operating Cash Flow
$3M
Free Cash Flow
$3M
Stock-Based Comp.
$735,000
Balance Sheet
Total Assets
$57M
Total Liabilities
$22M
Stockholders' Equity
$34M
Cash & Equivalents
$32M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$26M
$19M
+31.2%
Gross Profit
$16M
$12M
+35.7%
Operating Income
$2M
-$1M
+239.7%
Net Income
$2M
-$959,000
+295.8%
← FY 2024
All Quarters
Q4 2024 →